ⅡA分泌型磷脂酶A2与胃癌病理特征及预后的关系

Relationship between expression of secretory phospholipase A2 group Ⅱ A and clinicopathologic characteristics and prognosis in gastric carcinoma

目的:分析ⅡA分泌型磷脂酶A2(secretory phospholipase A2 groupⅡA,ⅡA sPLA2)在胃癌组织中的表达,研究ⅡA sPLA2表达与胃癌临床病理特征以及预后间的相关性.方法:收集因进展期胃癌(advanced gastric cancer,AGC)于2004-01/2005-01在福建医科大学附属第一医院行胃癌根治术的病理组织标本100例;采用MaxVision免疫组织化学法检测标本中ⅡA sPLA2的表达情况.Kaplan-Meier法分析胃癌患者的生存率,并通过Cox风险模型进行预后危险因素分析.结果:ⅡA sPLA2的表达水平与AGC的浸润深度、淋巴结转移有关(P<0.05),而与AGC患者的年龄、性别比例、发生部位、分化程度无关(P>0.05).ⅡA sPLA2高表达的患者术后生存率明显高于低表达的患者(P<0.05).性别、肿瘤浸润深度以及ⅡA sPLA2低表达是影响AGC患者术后生存率的独立危险因素.结论:ⅡA sPLA2表达水平下调与胃癌的临床病理特征以及胃癌患者的预后生存情况相关,ⅡA sPLA2低表达是胃癌预后评估的一个潜在的有效指标.

AIM： To detect the expression of secretory phospholipase A2 group II A （II A sPLA2） in gastric carcinoma, and to analyze its correlation with clinicopathologic characteristics and prog- nosis in patients with gastric carcinoma. METHODS： One hundred gastric carcinoma specimens were collected from patients who underwent surgery at the First Affiliated Hos- pital of Fujian Provincial University from Janu- ary 2004 to January 2005. The expression of II AsPLA2 protein in these specimens was detected by immunohistochemistry. The prognosis of patients with gastric cancer was analyzed us- ing the Kaplan-Meier curve. The risk factors influencing prognosis were evaluated by Cox regression analysis.RESULTS： The positive rate of II A sPLA2 ex- pression decreased remarkably in gastric carci- noma with pelvic lymph node metastasis or se- rosal invasion （P 〈 0.05）. The expression of II A sPLA2 in gastric carcinoma was not correlated with age, gender, tumor location or histologi- cal grade （P 〉 0.05）. Patients with higher levels of IIA sPLA2 expression had significantly extended survival （P 〈 0.05）. Serosal invasion, gender and lower II A sPLA2 expression were independent prognostic factors for patients with gastric cancer.CONCLUSION： II A sPLA2 expression level is related with clinicopathologic characteristics and survival in patients with gastric cancer, and IIA sPLA2 may be an ideal marker for prognosis evaluation in patients with gastric cancer.